Brown Brothers Harriman & Co’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $695K | Sell |
1,115
-687
| -38% | -$468K | ﹤0.01% | 611 |
|
|
2026
Q1 | $1.39M | Buy |
1,802
+737
| +69% | +$564K | 0.01% | 368 |
|
|
2025
Q4 | $822K | Buy |
1,065
+557
| +110% | +$378K | ﹤0.01% | 416 |
|
|
2025
Q3 | $286K | Buy |
508
+260
| +105% | +$147K | ﹤0.01% | 606 |
|
|
2025
Q2 | $130K | Sell |
248
-30
| -11% | -$16.7K | ﹤0.01% | 734 |
|
|
2025
Q1 | $176K | Sell |
278
-249
| -47% | -$171K | ﹤0.01% | 586 |
|
|
2024
Q4 | $375K | Buy |
527
+45
| +9% | +$37.8K | ﹤0.01% | 459 |
|
|
2024
Q3 | $507K | Sell |
482
-2
| -0.4% | -$2.23K | ﹤0.01% | 401 |
|
|
2024
Q2 | $509K | Sell |
484
-18
| -4% | -$17.4K | ﹤0.01% | 376 |
|
|
2024
Q1 | $483K | Sell |
502
-189
| -27% | -$180K | ﹤0.01% | 360 |
|
|
2023
Q4 | $607K | Buy |
691
+45
| +7% | +$37.1K | 0.01% | 330 |
|
|
2023
Q3 | $532K | Buy |
646
+302
| +88% | +$237K | ﹤0.01% | 335 |
|
|
2023
Q2 | $247K | Sell |
344
-247
| -42% | -$190K | ﹤0.01% | 439 |
|
|
2023
Q1 | $486K | Buy |
591
+22
| +4% | +$16.6K | ﹤0.01% | 345 |
|
|
2022
Q4 | $411K | Buy |
569
+204
| +56% | +$151K | ﹤0.01% | 342 |
|
|
2022
Q3 | $251K | Buy |
365
+1
| +0.3% | +$629 | ﹤0.01% | 414 |
|
|
2022
Q2 | $215K | Sell |
364
-14
| -4% | -$9.1K | ﹤0.01% | 450 |
|
|
2022
Q1 | $264K | Buy |
378
+47
| +14% | +$29.7K | ﹤0.01% | 456 |
|
|
2021
Q4 | $209K | Sell |
331
-239
| -42% | -$147K | ﹤0.01% | 473 |
|
|
2021
Q3 | $345K | Buy |
570
+6
| +1% | +$3.73K | ﹤0.01% | 371 |
|
|
2021
Q2 | $315K | Sell |
564
-127
| -18% | -$64.3K | ﹤0.01% | 364 |
|
|
2021
Q1 | $327K | Sell |
691
-1,025
| -60% | -$499K | ﹤0.01% | 338 |
|
|
2020
Q4 | $829K | Buy |
1,716
+69
| +4% | +$37.2K | 0.01% | 235 |
|
|
2020
Q3 | $922K | Sell |
1,647
-125
| -7% | -$75.8K | 0.01% | 209 |
|
|
2020
Q2 | $1.1M | Buy |
1,772
+1,321
| +293% | +$750K | 0.01% | 193 |
|
|
2020
Q1 | $220K | Sell |
451
-152
| -25% | -$62.7K | ﹤0.01% | 336 |
|
|
2019
Q4 | $226K | Buy |
603
+95
| +19% | +$32K | ﹤0.01% | 446 |
|
|
2019
Q3 | $141K | Buy |
508
+105
| +26% | +$31.1K | ﹤0.01% | 485 |
|
|
2019
Q2 | $126K | Sell |
403
-224
| -36% | -$74.6K | ﹤0.01% | 463 |
|
|
2019
Q1 | $257K | Sell |
627
-4
| -0.6% | -$1.65K | ﹤0.01% | 345 |
|
|
2018
Q4 | $236K | Hold |
631
| – | – | ﹤0.01% | 322 |
|
|
2018
Q3 | $255K | Buy |
631
+16
| +3% | +$6.09K | ﹤0.01% | 329 |
|
|
2018
Q2 | $212K | Hold |
615
| – | – | ﹤0.01% | 328 |
|
|
2018
Q1 | $212K | Sell |
615
-114
| -16% | -$39.7K | ﹤0.01% | 320 |
|
|
2017
Q4 | $274K | Sell |
729
-57
| -7% | -$23.1K | ﹤0.01% | 300 |
|
|
2017
Q3 | $351K | Sell |
786
-15
| -2% | -$7.14K | ﹤0.01% | 265 |
|
|
2017
Q2 | $393K | Sell |
801
-100
| -11% | -$43.8K | ﹤0.01% | 250 |
|
|
2017
Q1 | $349K | Buy |
901
+6
| +0.7% | +$2.22K | ﹤0.01% | 263 |
|
|
2016
Q4 | $329K | Buy |
895
+115
| +15% | +$43.7K | ﹤0.01% | 248 |
|
|
2016
Q3 | $314K | Sell |
780
-1
| -0.1% | -$401 | ﹤0.01% | 262 |
|
|
2016
Q2 | $273K | Sell |
781
-82
| -10% | -$31.6K | ﹤0.01% | 277 |
|
|
2016
Q1 | $311K | Sell |
863
-1,069
| -55% | -$441K | ﹤0.01% | 267 |
|
|
2015
Q4 | $1.05M | Hold |
1,932
| – | – | 0.01% | 187 |
|
|
2015
Q3 | $899K | Buy |
1,932
+7
| +0.4% | +$3.76K | ﹤0.01% | 197 |
|
|
2015
Q2 | $982K | Hold |
1,925
| – | – | ﹤0.01% | 200 |
|
|
2015
Q1 | $869K | Sell |
1,925
-400
| -17% | -$170K | ﹤0.01% | 213 |
|
|
2014
Q4 | $954K | Sell |
2,325
-75
| -3% | -$29.5K | ﹤0.01% | 203 |
|
|
2014
Q3 | $865K | Sell |
2,400
-300
| -11% | -$101K | ﹤0.01% | 209 |
|
|
2014
Q2 | $763K | Hold |
2,700
| – | – | ﹤0.01% | 225 |
|
|
2014
Q1 | $811K | Sell |
2,700
-2,700
| -50% | -$832K | ﹤0.01% | 198 |
|
|
2013
Q4 | $1.49M | Buy |
5,400
+2,700
| +100% | +$777K | ﹤0.01% | 205 |
|
|
2013
Q3 | $845K | Hold |
2,700
| – | – | ﹤0.01% | 188 |
|
|
2013
Q2 | $607K | Buy |
+2,700
| New | +$629K | ﹤0.01% | 261 |
|
Other funds holding REGN
Brown Brothers Harriman & Co's REGN Position: Q2 2026 in Review
Brown Brothers Harriman & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 38% in Q2 2026, selling an estimated $468K and leaving 1,115 shares worth $695K. The position accounts for ﹤0.01% of the portfolio, ranked #611.
Brown Brothers Harriman & Co first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.49M in Q4 2013. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Brown Brothers Harriman & Co held 1,115 shares of Regeneron Pharmaceuticals worth $695K as of Q2 2026.
- Brown Brothers Harriman & Co sold 687 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $468K.
- Regeneron Pharmaceuticals made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #611 holding.
- Brown Brothers Harriman & Co first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Brown Brothers Harriman & Co's Regeneron Pharmaceuticals position peaked at $1.49M in Q4 2013.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.